NCT07110753 The Effect of a Combined Lifestyle Intervention for Patients With Cancer on Quality of Life
| NCT ID | NCT07110753 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UMC Utrecht |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 244 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 244 participants in total. It began in 2025-08-01 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A growing number of people are living with the (long-term) consequences of cancer and its treatment, which can negatively affect their quality of life. This study aims to assess the effect of a combined lifestyle intervention for patients with cancer on quality of life.
Eligibility Criteria
Inclusion Criteria: * Be diagnosed with an invasive or hematological cancer type and either within five years post-primary treatment with curative intent OR having advanced cancer (stage IV) with a prolonged life expectancy (chronic cancer patients) . Primary treatment in this context, includes among others surgery (\> 3 months ago), radiotherapy, and/or chemotherapy or a stem cell transplant in case of hematological cancers. * Report a reduced HRQoL, i.e., a low score on at least 2 of the functioning scales and/or the symptom scale fatigue of the EORTC-QLQ-30 based on the thresholds of clinical importance of Giesinger et al. (2020) * Be 40 years of age or older. The investigators have chosen this cut-off because they believe that younger cancer patients (AYA's) face different challenges and should not be mixed with the average older patient. This approach ensures greater homogeneity within the study population. * Be able to speak and understand Dutch Exclusion Criteria: * Following, or planned to follow a combined lifestyle intervention (i.e., one of the existing interventions for overweight) during the intervention period * Patients in the terminal phase (life expectancy \< 3 months) * Mental or behavioural problems that hinder participating in group lifestyle coaching indicated by the health care professional who is referring to GLINK or by the study team * Any circumstances that would impede ability to give informed consent or adherence to study requirements as determined by the study team or treating physician
Contact & Investigator
Kristel van Asselt, PhD, MD
PRINCIPAL INVESTIGATOR
UMC Utrecht
Frequently Asked Questions
Who can join the NCT07110753 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07110753 currently recruiting?
Yes, NCT07110753 is actively recruiting participants. Contact the research team at a.manshanden@vu.nl for enrollment information.
Where is the NCT07110753 trial being conducted?
This trial is being conducted at Utrecht, Netherlands.
Who is sponsoring the NCT07110753 clinical trial?
NCT07110753 is sponsored by UMC Utrecht. The principal investigator is Kristel van Asselt, PhD, MD at UMC Utrecht. The trial plans to enroll 244 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.